|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Item 2.02. |
Results of Operations and Financial Condition.
|
Item 7.01. |
Regulation FD Disclosure.
|
Item 9.01. |
Financial Statements and Exhibits.
|
(d) |
Exhibits.
|
Press Release dated August 9, 2023 issued by STRATA Skin Sciences, Inc.
|
||
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
STRATA SKIN SCIENCES, INC.
|
|||
Date: August 9, 2023
|
By:
|
/s/ Christopher Lesovitz
|
|
Christopher Lesovitz
|
|||
Chief Financial Officer
|
● |
Revenues in the second quarter of 2023 were $8.3 million, compared to $9.1 million for the second quarter of 2022.
|
● |
Secured up to an additional $12 million financing with MidCap Financial.
|
● |
Placed 73 TheraClear®X devices as of June 30, 2023.
|
For the Three Months Ended June
30,
|
||||||||
2023
|
2022
|
|||||||
Net loss
|
$
|
(3,148
|
)
|
$
|
(1,892
|
)
|
||
Adjustments:
|
||||||||
Depreciation and amortization
|
1,428
|
1,339
|
||||||
Amortization of operating lease right-of-use assets
|
63
|
92
|
||||||
Loss on disposal of property and equipment
|
24
|
18
|
||||||
Interest expense, net
|
277
|
198
|
||||||
Non-GAAP EBITDA
|
(1,356
|
)
|
(245
|
)
|
||||
Stock-based compensation expense
|
352
|
452
|
||||||
Loss on debt extinguishment
|
909
|
—
|
||||||
Non-GAAP adjusted EBITDA
|
$
|
(95
|
)
|
$
|
207
|
Three Months Ended
June 30,
|
||||||||
2023
|
2022
|
|||||||
Gross domestic recurring billings
|
$
|
5,057
|
$
|
5,956
|
||||
Co-Pay adjustments
|
(88
|
)
|
(204
|
)
|
||||
Other discounts
|
(31
|
)
|
(46
|
)
|
||||
Deferred revenue from prior quarters
|
2,025
|
1,970
|
||||||
Deferral of revenue to future quarters
|
(2,005
|
)
|
(2,499
|
)
|
||||
GAAP Recorded domestic revenue
|
$
|
4,958
|
$
|
5,177
|
June 30, 2023
|
December 31,
2022
|
|||||||
(unaudited)
|
||||||||
Assets
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
9,034
|
$
|
5,434
|
||||
Restricted cash
|
1,361
|
1,361
|
||||||
Accounts receivable, net of allowance for credit losses of $244 and $382 at June 30, 2023 and December 31, 2022, respectively
|
4,401
|
4,471
|
||||||
Inventories
|
5,921
|
5,547
|
||||||
Prepaid expenses and other current assets
|
528
|
691
|
||||||
Total current assets
|
21,245
|
17,504
|
||||||
Property and equipment, net
|
8,319
|
7,498
|
||||||
Operating lease right-of-use assets
|
807
|
975
|
||||||
Intangible assets, net
|
15,959
|
17,394
|
||||||
Goodwill
|
8,803
|
8,803
|
||||||
Other assets
|
71
|
98
|
||||||
Total assets
|
$
|
55,204
|
$
|
52,272
|
||||
Liabilities and Stockholders’ Equity
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
3,880
|
$
|
3,425
|
||||
Accrued expenses and other current liabilities
|
6,731
|
6,555
|
||||||
Deferred revenues
|
2,436
|
2,778
|
||||||
Current portion of operating lease liabilities
|
392
|
355
|
||||||
Current portion of contingent consideration
|
681
|
313
|
||||||
Total current liabilities
|
14,120
|
13,426
|
||||||
Long-term debt, net
|
14,987
|
7,476
|
||||||
Deferred revenues and other liabilities
|
596
|
314
|
||||||
Deferred tax liability
|
306
|
306
|
||||||
Operating lease liabilities, net of current portion
|
387
|
610
|
||||||
Contingent consideration, net of current portion
|
7,899
|
8,309
|
||||||
Total liabilities
|
38,295
|
30,441
|
||||||
Commitments and contingencies
|
||||||||
Stockholders’ equity:
|
||||||||
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized; no shares issued and outstanding
|
—
|
—
|
||||||
Common stock, $0.001 par value; 150,000,000 shares authorized; 34,881,453 and 34,723,046 shares issued and outstanding at June 30,
2023 and December 31, 2022, respectively
|
35
|
35
|
||||||
Additional paid-in capital
|
250,085
|
249,024
|
||||||
Accumulated deficit
|
(233,211
|
)
|
(227,228
|
)
|
||||
Total stockholders’ equity
|
16,909
|
21,831
|
||||||
Total liabilities and stockholders’ equity
|
$
|
55,204
|
$
|
52,272
|
Three Months Ended June 30,
|
||||||||
2023
|
2022
|
|||||||
Revenues, net
|
$
|
8,250
|
$
|
9,105
|
||||
Cost of revenues
|
3,932
|
4,112
|
||||||
Gross profit
|
4,318
|
4,993
|
||||||
Operating expenses:
|
||||||||
Engineering and product development
|
374
|
209
|
||||||
Selling and marketing
|
3,416
|
4,146
|
||||||
General and administrative
|
2,490
|
2,332
|
||||||
6,280
|
6,687
|
|||||||
Loss from operations
|
(1,962
|
)
|
(1,694
|
)
|
||||
Other (expense) income:
|
||||||||
Loss on debt extinguishment
|
(909
|
)
|
—
|
|||||
Interest expense
|
(298
|
)
|
(208
|
)
|
||||
Interest income
|
21
|
10
|
||||||
(1,186
|
)
|
(198
|
)
|
|||||
Net loss
|
$
|
(3,148
|
)
|
$
|
(1,892
|
)
|
||
Net loss per share of common stock, basic and diluted
|
$
|
(0.09
|
)
|
$
|
(0.05
|
)
|
||
Weighted average shares of common stock outstanding, basic and diluted
|
34,881,453
|
34,723,046
|
For the Six Months Ended June 30,
|
||||||||
2023
|
2022
|
|||||||
Cash flows from operating activities:
|
||||||||
Net loss
|
$
|
(5,983
|
)
|
$
|
(4,394
|
)
|
||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Depreciation and amortization
|
1,390
|
1,224
|
||||||
Amortization of operating lease right-of-use assets
|
168
|
181
|
||||||
Amortization of intangible assets
|
1,435
|
1,436
|
||||||
Amortization of deferred financing costs and debt discount
|
83
|
76
|
||||||
Change in allowance for credit losses
|
(138
|
)
|
(47
|
)
|
||||
Stock-based compensation expense
|
677
|
820
|
||||||
Loss on disposal of property and equipment
|
24
|
35
|
||||||
Loss on debt extinguishment
|
909
|
—
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
208
|
491
|
||||||
Inventories
|
(272
|
)
|
(898
|
)
|
||||
Prepaid expenses and other assets
|
190
|
(203
|
)
|
|||||
Accounts payable
|
351
|
1,419
|
||||||
Accrued expenses and other liabilities
|
211
|
(217
|
)
|
|||||
Deferred revenues
|
(95
|
)
|
(135
|
)
|
||||
Operating lease liabilities
|
(186
|
)
|
(197
|
)
|
||||
Net cash used in operating activities
|
(1,028
|
)
|
(409
|
)
|
||||
Cash flows from investing activities:
|
||||||||
Purchase of property and equipment
|
(2,337
|
)
|
(1,510
|
)
|
||||
Cash paid in connection with TheraClear asset acquisition
|
—
|
(631
|
)
|
|||||
Net cash used in investing activities
|
(2,337
|
)
|
(2,141
|
)
|
||||
Cash flows from financing activities:
|
||||||||
Proceeds from long-term debt
|
7,000
|
—
|
||||||
Payment of deferred financing costs
|
(35
|
)
|
—
|
|||||
Net cash provided by financing activities
|
6,965
|
—
|
||||||
Net increase (decrease) in cash, cash equivalents and restricted cash
|
3,600
|
(2,550
|
)
|
|||||
Cash, cash equivalents and restricted cash, beginning of period
|
6,795
|
12,586
|
||||||
Cash, cash equivalents and restricted cash, end of period
|
$
|
10,395
|
$
|
10,036
|
||||
Cash and cash equivalents
|
$
|
9,034
|
$
|
10,036
|
||||
Restricted cash
|
1,361
|
—
|
||||||
|
$
|
10,395
|
$
|
10,036
|
||||
Supplemental disclosure of cash flow information:
|
||||||||
Cash paid for interest
|
$
|
497
|
$
|
329
|
||||
Supplemental disclosure of non-cash operating, investing and financing activities:
|
||||||||
Inventories acquired in connection with TheraClear asset acquisition
|
$
|
—
|
$
|
71
|
||||
Intangible assets acquired in connection with TheraClear asset acquisition
|
$
|
—
|
$
|
10,182
|
||||
Contingent consideration issued in connection with TheraClear asset acquisition
|
$
|
—
|
$
|
9,122
|
||||
Common stock issued in connection with TheraClear asset acquisition
|
$
|
—
|
$
|
500
|
||||
Modification of common stock warrants
|
$
|
384
|
$
|
—
|
||||
Transfer of property and equipment to inventories
|
$
|
102
|
$
|
449
|
||||
Accrued payment of contingent consideration
|
$
|
42
|
$
|
—
|
||||
Accrued exit fee recorded as debt discount
|
$
|
450
|
$
|
—
|
||||
Deferred financing costs in accounts payable
|
$
|
62
|
$
|
—
|
Document and Entity Information |
Aug. 09, 2023 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Aug. 09, 2023 |
Entity File Number | 000-51481 |
Entity Registrant Name | STRATA SKIN SCIENCES, INC. |
Entity Central Index Key | 0001051514 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 13-3986004 |
Entity Address, Address Line One | 5 Walnut Grove Drive |
Entity Address, Address Line Two | Suite 140 |
Entity Address, City or Town | Horsham |
Entity Address, State or Province | PA |
Entity Address, Postal Zip Code | 19044 |
City Area Code | 215 |
Local Phone Number | 619-3200 |
Title of 12(b) Security | Common Stock, $0.001 par value per share |
Trading Symbol | SSKN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
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end
:4AJQ)RH\X&(E2
ME3 91+L%V^K9I.?]4590T+M*2$KWYQS<'H'^! ^;@P;N#KZ-4Y1 _.L?E:
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M)P)06["O6UZK01_&G+?KI(BX%'7W3(KVQ$O%HP5)IE(I* 2UR4(&63!8./G)_"SP5KFKK\:/Q=UGYV?RZ#H:K&$G*,>3\P5!R)WXIE@M(:Q6:ZV
MDH"%PP]8>M!U7P2M%E:UVH:URB9RTWFJ38BY[V]'^,%\IP*\HJHZZU)\4IWT
M\M-CU6DLX<(G!=:_RL=7\B1PGI#NCW)5].3A#08ZXROK7&]4L7FUX=[H(EE4.)@=WV^=[)KI-=>K+;Z=,WJS?/]W:[
MU$%[14/EJ\IX3,\F(0M.9/%DK1 0^%[06G)7#3$4(*.&';MN=_NWZ[4;]!.3
M2&@>&H[TJJ>HV ?C;L"^&)O4:,@P$'
M \^!@98%%77L 0'*60D/64CF\VN!S(O=Q]%BW*575$1!@VD8JVO-AJD:@]ET
M)?2"S42A% I9R".+4I:49W!I!([#2'#8/NS9-UNK'IW*TW"$47973]EM'-+9
M. R\9I-^7)"D+>O$D=+P=T,12/EI+'AY2!O\4# YM,1O$ YM_5(,-*V5MFUI=#O)CG1R8F3
MDP>U?Z=)_Y"*VZ*GO46_+-Q,5(7S0!(W(D@
MC^=J3]6C